Abstract: FR-PO209
Onconephrology, Rise of the Unknowns: Enhertu-Induced Fanconi Syndrome
Session Information
- Onconephrology: Clinical and Research Advances - I
November 04, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
Abstract Time: 10:00 AM - 12:00 PM
Category: Onconephrology
- 1600 Onconephrology
Authors
- Kalantri, Pooja, Emory University, Atlanta, Georgia, United States
- Lomashvili, Koba A., Emory University, Atlanta, Georgia, United States
Introduction
Kidney toxicities are associated with increasingly complex and constantly emerging cancer treatment protocols. Data clearly demonstrates that when patients with cancer develop acute or chronic kidney disease, severe fluid and electrolyte abnormalities, outcomes are inferior, and the promise of curative therapeutic regimens is lessened. Here we present a case of a new chemotherapeutic agent and the electrolyte abnormalities that it has caused.
Case Description
A 74-year-old woman with metastatic, recurrent ER+/PR-/HER2+ invasive ductal carcinoma of the right breast, status post bilateral mastectomies, chemo, radiation, and hormonal therapies, who, while being on Herceptin/Perjecta maintenance for a year, experienced progression. She was started on Enhertu (Herceptin+Deruxtecan), but due to worsening diarrhea, >12 episodes a day, decreased oral intake and weight loss, was admitted to the hospital. Her blood pressures were soft. Labs showed sodium 132 mmol/L, potassium 2.1 mmol/L, bicarbonate 17 mmol/L, anion gap 6, calcium 7.3 mg/dL, magnesium 1.2 mg/dL, phosphorus 1.3 mg/dL. Abnormalities persisted with improving diarrhea. Urine was positive for protein and glucose, with pH 5. Urine anion gap was negative, but eventually turned positive with improving diarrhea. Transtubular potassium gradient was 8. This was consistent with component of diarrhea causing acidosis, whereas there was also evidence of Fanconi syndrome with glucosuria, proteinuria, and renal potassium and phosphate wasting. The Fanconi syndrome was attributed to the Deruxtecan component of Enhertu, as she was previously on Herceptin. Enhertu was stopped, and her electrolyte abnormalities resolved over a course of 2 months.
Discussion
Deruxtecan has been associated with diarrhea (20-30%) and hypokalemia (1-12%) in phase 2 trials. But there has been no mention about Fanconi syndrome. We report a case of reversible Fanconi syndrome due to Enhertu. It is important to recognize this as future doses of this medication may cause poor outcomes in these patients, while the performance status can be improved again by recognizing this reversible cause.